<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Vernakalant is a new antiarrhythmic agent recently approved in Europe for the rapid cardioversion of recent <z:hpo ids='HP_0003674'>onset</z:hpo> <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It works by blocking early-activating K+ atrial channels and frequency-dependent atrial <z:chebi fb="1" ids="29101">Na+</z:chebi> channels, prolonging atrial refractory periods and rate-dependent slowing atrial conduction, without promoting <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Pre-clinical and clinical trials showed good toleration of this drug </plain></SENT>
<SENT sid="3" pm="."><plain>The main purpose of our review is to describe <z:hpo ids='HP_0000001'>all</z:hpo> the trials that led to the incorporation of Vernakalant into the current European <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> guidelines. Â© 2013 Blackwell Publishing Ltd </plain></SENT>
</text></document>